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MICROENCAPSLATION OF MUSHROOM EXTRACTS 
FOR COSMECEUTICAL DESIGN 
Taofiq, 0.1'2'3 , Heleno, S.A.1'2 , Barros, L. 1'2 , Calhelha, R.C.1, Alves, M.J.1, Fernandes, I.P.2, Gonzalez-Paramas, A.M.3 , 
Barreiro, M.F?, Ferreira, I.C.F.R.1 
INTRODUCTION & OBJECTIVES 
The global cosmetic industry is constantly in search for bio 
based ingredients with less toxic effects but providing 
multifunctional properties, maintaining the structure and 
function of the skin. This will, thereby, reduce the presence of 
synthetic ingredients in personal care products (Taofiq, 2017). 
Cosmeceuticals are the newest trend in the design of personal 
care products, presenting medical drug-like benefits through 
the supply of appropriate ingredients for the maintenance of a 
healthy skin. They include bioactive compounds such as 
phytonutrients, microbial metabolites, minerals, vitamins and 
animal proteins (Taofiq, 2016a). 
Mushrooms are widely consumed due to their rich nutritional 
composition with recognized health promoting benefits. They 
contain several bioactive compounds such as 
polysaccharides, phenolics, terpenoids, nucleotides, steroids, 
fatty acids, proteins and glycol-peptides that are responsible 
for their antioxidant, antitumor, anti-inflammatory, antimicrobial 
anti-tyrosinase and other biological activities. Because of all 
the above-mentioned properties, there is an increasing interest 
in incorporating mushroom extracts and/or their isolated 
compounds in cosmetic formulations, expecting positive 
benefits on the skin. These extracts/compounds can act either 
as antioxidants, preservatives or as hyperpigmentation 
correcting agents (Taofiq, 2016a). 
In a general way, the use of natural-derived extracts, including 
mushroom extracts, as cosmeceutical ingredients can present 
restrictions related with the lack of stability and ease 
degradation of some of their metabolites. To overcome these 
challenges, microencapsulation techniques have been utilised 
taking advantage of the protection conferred by polymeric 
materials, particularly natural-derived and biodegradable ones. 
This ensures protection against oxidation and degradation, 
controlled or target oriented release, guaranteeing that the 
bioactives effectively cross the biological membranes. 
The specific objective of the present work was to obtain 
mushroom extracts-based ingredients for cosmeceutical 
applications. Soxhlet ethanolic extracts were prepared from 
Agaricus bisporus (J.E.Lange) lmbach (A) and Pleurotus 
ostreatus (Jacq. ex Fr.) P.Kumm (P), thereafter chemically 
characterised in terms of phenolic acids and ergosterol 
contents, and screened for their anti-inflammatory, 
antimicrobial, antioxidant, and anti-tyrosinase activities. The 
extracts were then microencapsulated in calcium alginate 
particles by an atomization/coagulation technique. The 
produced microparticles were characterised (morphology, 
particle size, encapsulation efficiency (EE%)) for subsequent 
incorporation in a base cosmetic cream. The developed 
formulations were evaluated for their bioactive properties, pH 
and colour evolution over a 6 months' period to ascertain the 
stability of the bioactives and monitor their in vitro release 
behaviour. The composition of the bioactive compounds in the 
creams was also monitored by HPLC. 
MATERIALS & METHODS 
Mushroom extracts were prepared by the soxhlet methodology 
using ethanol as solvent. Their antioxidant activity was 
evaluated by DPPH radical-scavenging activity, and reducing 
inflammatory activity was evaluated by quantification of NO 
production in RAW 264.7 macrophages cells. The 
microdilution method was used to determine the minimum 
inhibitory concentrations (MICs) of the extracts. The tyrosinase 
inhibition assay was evaluated using L-DOPA as substrata 
(Taofiq, 2016b ). 
The chemical characterization of both extracts and final 
formulations included the analysis of ergosterol by HPLC-UV, 
and of the phenolic compounds by HPLC-DAD. 
Microencapsulation of the mushroom extracts was done by the 
atomization/coagulation method with sodium alginate 
coagulated with calcium chloride. Briefly, sodium alginate 
solutions (4%, w/v) containing the extracts were prepared 
under stirring at ambient temperature using a ratio 
extract:alginate of 100:400 (w/w). The solutions were atomized 
in a Nisco Var J30 unit and microparticles coagulated upon 
contact with a solution of CaCI2 (4%, w/v). This coagulation 
solution was recovered after vacuum filtration to obtain the 
microparticles that were thereafter washed with deionized 
water. 
The obtained microparticles were analyzed by optical 
microscopy (OM) and characterized in what concerns particle 
size distribution (Mastersizer 3000 based on laser diffraction 
technique). The EE% of the encapsulation system was 
deduced from the quantification of the non-encapsulated 
bioactives though the analysis of the recovered coagulation 
and washing solutions. 
Free and microencapsulated extracts were incorporated in a 
Fagron Versatile TM vanishing o/w base cream. The 
formulations were stored in glass vials, and the bioactivities 
and chemical characterization carried out accordingly as 
previously described. The colour was measured using a 
colorimeter based on the L *a*b* system and the pH using HI 
99161 pH-meter. 
RESULTS & DISCUSSION 
The phenolic acids found in P were cinnamic, p-
hydroxybenzoic and p-coumaric acids (Total- 584 ± 3 IJg/g) 
while only cinnamic acid (90.1 ± 0.7 iJg/g) was detected in A. 
The ergosterol content was 44.8 ± 0.4 and 78.2 ± 0.5 (mg/g) 
for A and P, respectively. The bioactive properties displayed 
by A and P were as follows (ECso values in mg/ml): anti-
inflammatory (0.18 ± 0.01 and 0.29 ± 0.03, respectively}, anti-
tyrosinase (0.16 ± 0.01 and 0.86 ± 0.07), DPPH radical-
scavenging activity (7.0 ± 0.3 and 7.7 ± 0.2), reducing power 
(2.34 ± 0.05 and 2.36 ± 0.08). Up to 10 mg/ml, the growth of 
E. faecalis, MSSA and MRSA was inhibited. These bioactive 
properties of A and P highlight the obtained extracts as 
interesting cosmeceutical ingredients with multifunctional 
properties. 
The concentration of phenolic acids in the coagulation and 
washing solutions was determined to calculate the EE% giving 
rise to values of 97.5 and 99.9 for A and P, respectively. 
These results showed that the extracts were successfully 
encapsulated. The analysis of the microparticles by MO 
showed the presence of spherical and individualized 
structures with little or no agglomeration. 
The particle sizes were measured as d10, d50 and d90 
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number were 0.719, 0.937 and 2.05 IJm, while for P 
microparticles were 0. 715, 0.920 and 1.96 IJm respectively. 
Concerning the d10, d50 and d90 percentiles in volume, the 
values were 27.1, 100 and 254 IJm for A and 27.7, 94.7 and 
240 IJm for P microparticles respectively. In conclusion, 
nevertheless the used active principle (A or P), the obtained 
microparticles showed similar properties in terms of size 
distribution. Additionally, the particle size distributions in 
number are unimodal, while distributions in volume are 
bimodal as it can be observed in Figure 1 (a) and (b), 
respectively. 
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Figure 1. Microparticles size distributions expressed 
as mean (a) number distributions and (b) volume 
distributions. 
The developed cosmeceutical formulations presented, along 
the storage time, a pH value comprised between 3.4 and 4.4, 
which is a suitable pH range for cosmetic preservation as most 
of the pathogenic bacteria thrive best at neutral pH. The L * 
(lightness) parameter was the colour parameter showing the 
more pronounced variation among the three monitored 
variables. Significant colour changes could not be observed, 
which was attributed to the stability of the formulations, as 
degradation was not significant enough to produce end-
products that may influence the colour of the formulations. 
In the base creams with the A and P extracts, the total 
phenolic acids were 88 ± 2 IJg/g and 509 ± 4 IJg/g, 
respectively, immediately after incorporation. This means that 
the target compounds were successively incorporated, being 
detected up to 80% of the amount determined for the 
corresponding free extracts. Nevertheless, loss of bioactive 
compounds was found over the 6-month period of storage, but 
significant bioactivity was still achieved. 
The cosmeceutical formulations prepared with the free 
extracts presented antioxidant, anti-tyrosinase and 
antimicrobial activities, while the formulations prepared with 
the microencapsulated extracts only displayed anti-tyrosinase 
and antimicrobial activities. These results show that even 
though the extracts have been well encapsulated, their in vitro 
release behaviour, particularly in what concerns the 
antioxidant activity, could not be rationally understood. This 
suggests the need to conduct further studies to better 
understand the showed behaviour. 
CONCLUSION & PERSPECTIVES 
The above findings reveal that ethanolic extracts of A. 
bisporus and P. ostreatus, display strong antioxidant, 
antibacterial, anti-inflammatory and anti-tyrosinase activities, 
mainly due to the contribution of their bioactive components, 
being suitable for multifunctional personal care ingredients. 
The atomization/coagulation technique was successfully 
applied to microencapsulated the extracts, giving rise to high 
encapsulation efficiencies (97.5 and 99.9, respectively for A 
and P). The incorporation of both free and protected 
(microencapsulated) extracts, into the base cosmetic creams, 
was able to impart bioactivity to the final products. Further 
studies need to be conducted to better understand the 
differences found between the two used forms (free and 
microencapsulated extracts). Additionally, this in course study 
will proceed with the study of other encapsulation materials. 
Also, in vitro skin permeation studies need to be conducted to 
determine the topical bioavailability of these bioactive 
ingredients. 
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